Interim Report 2026
Filed with HKEX · Stock code 1672 · · 65 pages · English
2 Corporate Information 3 Financial Highlights 4 Management Discussion and Analysis 29 Other Information 39 Independent Review Report 40 Consolidated Statement of Profit or Loss 41 Consolidated Statement of Profit or Loss and Other Comprehensive Income 42 Consolidated Statement of Financial Position 44 Consolidated Statement of Changes in Equity 46 Condensed Consolidated Cash Flows Statement 47 No
Earlier from Ascletis Pharma
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
- Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
Later from Ascletis Pharma
- Voluntary announcement - ascletis' ASC36_35FDC demonstrated potential for once-monthly to once-quarterly dosing and robust weight-loss in preclinical studies presented at EASD 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
- Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity
Follow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma